Sydney Gilman Net Worth

Sydney Gilman biography

Dr. Sydney Gilman, Ph.D. is appointed as Vice President - Regulatory Affairs of the Company effective November 1, 2019. Dr. Gilman is currently the founder and President of Trident Rx Consulting Services LLC, a regulatory consulting firm, a position he has held since January 2004. Dr. Gilman is a former U.S. Food and Drug Administration (“FDA”) Chemistry reviewer. He spent six years at the FDA in various Center for Drug Evaluation and Research Therapeutic Drug Divisions of the Center for Drug Evaluation and Research with consulting ties to both Biologics and Devices. Dr. Gilman also has an additional 20 years of experience in the pharmaceutical industry in positions ranging from Senior Scientist to Director to Vice President Responsibilities. He earned a Bachelor of Science degree from Loyola College and a Ph.D. in Organic Chemistry from the University of Pittsburgh. Dr. Gilman has been providing regulatory consulting services to DiaMedica since June 2019.

What's Sydney Gilman's mailing address?

Sydney's mailing address filed with the SEC is TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS, MN, 55447.

Insiders trading at DiaMedica Therapeutics

Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg a David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.

What does DiaMedica Therapeutics do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics executives and stock owners

DiaMedica Therapeutics executives and other stock owners filed with the SEC include:

• Dietrich John Pauls MBA,
  Pres, CEO & Director
• Rick Pauls,
  President, Chief Executive Officer, Director
• Dr. Harry W. Alcorn Jr., Pharm.D.,
  Sr. VP of Clinical Operations
• Scott B. Kellen C.A.,
  CFO & Company Sec.
• James Parsons,
  Director
• Michael Giuffre,
  Independent Director
• Jerry Xiao,
  Director
• Harry Alcorn,
  Director
• Paul Papi,
  Vice President - Business Development
• Sydney Gilman,
  Vice President - Regulatory Affairs
• Scott Kellen,
  Chief Financial Officer, Corporate Secretary
• Richard Pilnik,
  Independent Chairman of the Board
• Dr. Edward G. Calamai Ph.D.,
  Consulting Head of Manufacturing
• Tanya Lewis,
  Director
• David J. Wambeke,
  Chief Business Officer
• Jantrill Ab Stahlberg,
  
• Dietrich John Pauls,
  President and CEO
• Zhenyu Xiao,
  Director
• Todd A. Verdoorn,
  Chief Scientific Officer
• Koch Thomas Tom Enterprise ...,
  
• Koch Thomas Tom Enterprise ...,
  
• Charles Pauling Semba,
  Director
• Amy L. Burroughs,
  Director
• Kirsten L Gruis,
  Chief Medical Officer
• Dominic R Cundari,
  Chief Commercial Officer
• Julie Van Orsdel Daves,
  SVP Clinical Development Oper.
• Masuoka K. Lorianne,
  Chief Medical Officer
• Richard Kuntz,
  Director